Stéphane Verguet1, Zachary D Olson2, Joseph B Babigumira2, Dawit Desalegn3, Kjell Arne Johansson4, Margaret E Kruk5, Carol E Levin2, Rachel A Nugent2, Clint Pecenka6, Mark G Shrime7, Solomon Tessema Memirie4, David A Watkins8, Dean T Jamison2. 1. Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA. Electronic address: verguet@hsph.harvard.edu. 2. Department of Global Health, University of Washington, Seattle, WA, USA. 3. Addis Ababa University, College of Health Sciences, School of Medicine, Addis Ababa, Ethiopia. 4. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. 5. Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 6. PATH, Seattle, WA, USA. 7. Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA; Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 8. Department of Medicine, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: The way in which a government chooses to finance a health intervention can affect the uptake of health interventions and consequently the extent of health gains. In addition to health gains, some policies such as public finance can insure against catastrophic health expenditures. We aimed to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. METHODS: We used extended cost-effectiveness analysis to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine (among many other) interventions that the Government of Ethiopia aims to make universally available. These nine interventions were measles vaccination, rotavirus vaccination, pneumococcal conjugate vaccination, diarrhoea treatment, malaria treatment, pneumonia treatment, caesarean section surgery, hypertension treatment, and tuberculosis treatment. FINDINGS: Our analysis shows that, per dollar spent by the Ethiopian Government, the interventions that avert the most deaths are measles vaccination (367 deaths averted per $100,000 spent), pneumococcal conjugate vaccination (170 deaths averted per $100,000 spent), and caesarean section surgery (141 deaths averted per $100,000 spent). The interventions that avert the most cases of poverty are caesarean section surgery (98 cases averted per $100,000 spent), tuberculosis treatment (96 cases averted per $100,000 spent), and hypertension treatment (84 cases averted per $100,000 spent). INTERPRETATION: Our approach incorporates financial risk protection into the economic evaluation of health interventions and therefore provides information about the efficiency of attainment of both major objectives of a health system: improved health and financial risk protection. One intervention might rank higher on one or both metrics than another, which shows how intervention choice-the selection of a pathway to universal health coverage-might involve weighing up of sometimes competing objectives. This understanding can help policy makers to select interventions to target specific policy goals (ie, improved health or financial risk protection). It is especially relevant for the design and sequencing of universal health coverage to meet the needs of poor populations.
BACKGROUND: The way in which a government chooses to finance a health intervention can affect the uptake of health interventions and consequently the extent of health gains. In addition to health gains, some policies such as public finance can insure against catastrophic health expenditures. We aimed to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. METHODS: We used extended cost-effectiveness analysis to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine (among many other) interventions that the Government of Ethiopia aims to make universally available. These nine interventions were measles vaccination, rotavirus vaccination, pneumococcal conjugate vaccination, diarrhoea treatment, malaria treatment, pneumonia treatment, caesarean section surgery, hypertension treatment, and tuberculosis treatment. FINDINGS: Our analysis shows that, per dollar spent by the Ethiopian Government, the interventions that avert the most deaths are measles vaccination (367 deaths averted per $100,000 spent), pneumococcal conjugate vaccination (170 deaths averted per $100,000 spent), and caesarean section surgery (141 deaths averted per $100,000 spent). The interventions that avert the most cases of poverty are caesarean section surgery (98 cases averted per $100,000 spent), tuberculosis treatment (96 cases averted per $100,000 spent), and hypertension treatment (84 cases averted per $100,000 spent). INTERPRETATION: Our approach incorporates financial risk protection into the economic evaluation of health interventions and therefore provides information about the efficiency of attainment of both major objectives of a health system: improved health and financial risk protection. One intervention might rank higher on one or both metrics than another, which shows how intervention choice-the selection of a pathway to universal health coverage-might involve weighing up of sometimes competing objectives. This understanding can help policy makers to select interventions to target specific policy goals (ie, improved health or financial risk protection). It is especially relevant for the design and sequencing of universal health coverage to meet the needs of poor populations.
Authors: Gene Bukhman; Ana O Mocumbi; Rifat Atun; Anne E Becker; Zulfiqar Bhutta; Agnes Binagwaho; Chelsea Clinton; Matthew M Coates; Katie Dain; Majid Ezzati; Gary Gottlieb; Indrani Gupta; Neil Gupta; Adnan A Hyder; Yogesh Jain; Margaret E Kruk; Julie Makani; Andrew Marx; J Jaime Miranda; Ole F Norheim; Rachel Nugent; Nobhojit Roy; Cristina Stefan; Lee Wallis; Bongani Mayosi Journal: Lancet Date: 2020-09-14 Impact factor: 79.321
Authors: Clinton J Pecenka; Kjell Arne Johansson; Solomon Tessema Memirie; Dean T Jamison; Stéphane Verguet Journal: BMJ Open Date: 2015-05-03 Impact factor: 2.692
Authors: Olga P M Saweri; Neha Batura; Rabiah Al Adawiyah; Louise M Causer; William S Pomat; Andrew J Vallely; Virginia Wiseman Journal: PLoS One Date: 2021-06-17 Impact factor: 3.240